デジタルセラピューティクス - 世界市場の考察、競合情勢、市場予測（2030年）

世界のデジタルセラピューティクスの市場規模は、2024年～2030年の予測期間にCAGRで27.73%の成長が見込まれます。デジタルセラピューティクスの需要は、糖尿病、精神疾患、がん、心不全（HF）などの慢性疾患の有病率の増加、モバイル技術、ウェアラブル機器、AI、機器学習、データアナリティクスの継続的な進歩などの技術の進歩により、より洗練された効果的なデジタルセラピューティクスソリューションの開発が促進されています。多くの国々で医療費は着実に増加しています。デジタルセラピューティクスは、遠隔で効率的な医療を提供し、頻繁な通院の必要性を減らし、慢性疾患に伴うコストのかかる合併症を予防することで、医療費を削減する機会を提供します。規制当局の支援、医療従事者の間での受け入れの拡大、医療保険の適用、戦略的パートナーシップや投資などが、デジタルセラピューティクス市場全体の成長に寄与し、2024年～2030年の予測期間に市場成長を促進する主な要因です。

デジタルセラピューティクスの市場力学

International Diabetes Federation（2022）によると、2021年に世界で約5億3,700万人が糖尿病を患っていました。前述の資料によると、糖尿病に苦しむ患者の総数は、2030年までに約6億4,300万人、2045年までに約7億8,300万人に増加すると予測されています。

Blue Star, Diabeo System、Livongo Diabetes Program、Tidepoolなどのデジタルセラピューティクス（DTx）アプリケーションは、ウェブベースのアプリケーションやクラウドプラットフォームを使用し、糖尿病を含む行動変容可能な慢性疾患の、エビデンスに基づく個別化された迅速なポイントオブケア管理を提供します。DTxは、患者の積極的な関与、ライフスタイルの変更、包括的な医療、血糖状態の定期的なモニタリングを可能にすることにより、糖尿病管理における患者コンプライアンス、治療の成功、経済的成果を改善することができます。このように、糖尿病有病率の増加は、糖尿病の管理と治療に使用されるデジタルセラピューティクスソフトウェアの需要を増加させ、デジタルセラピューティクス市場全体を促進します。

先進国、新興国市場ともにスマートフォンの普及が進んでいることや、患者や医療提供者にとってデジタルヘルス技術が手頃な価格で利用できること、患者中心のケアや統合医療システムに対する需要が高まっていることなどが市場を牽引すると予測されます。Kepiosは2021年4月に世界で42億7,000万人がインターネットを利用し、世界人口の60%以上を占めると推定しています。この数字が増えるにつれて、スマートヘルストラッキングに対する人々の意識も高まることが予測されます。さらに、COVID-19パンデミック、有用な規制措置、償還の早期の兆候、慢性疾患の有病率の向上が市場拡大を促進すると予測されます。

医師や患者が簡単にアクセスできる、このような先進技術を利用したソフトウェアの開発への大手主要企業の注力は、予測期間に市場を推進すると予測されます。例えば、2022年7月、AmerisourceBergen Corporationは医師が指示した治療や診断への患者のアクセスを容易にすることを目的とした、完全統合型の注文、調剤、フルフィルメントプラットフォームであるDTx Connectを発表しました。このプラットフォームは電子カルテ（EMR）と統合されており、医師は処方薬や非処方薬に簡単にアクセスできます。

したがって、上記の要因が2024年～2030年の予測期間のデジタルセラピューティクス市場の成長に寄与しています。

しかし、サイバーセキュリティやプライバシーに関する懸念、不安定な決済モデルなどが、デジタルセラピューティクス市場の成長を抑制する可能性があります。

デジタルセラピューティクス市場のセグメント分析

デジタルセラピューティクス市場の適応症セグメントでは、肥満カテゴリが2023年に大きな収益シェアを獲得すると予測されています。これは、世界中で肥満の統計値が増加していることに起因しています。

当レポートでは、世界のデジタルセラピューティクス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 デジタルセラピューティクス市場レポートのイントロダクション

第2章 デジタルセラピューティクス市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 デジタルセラピューティクス市場の主な要因の分析

• デジタルセラピューティクス市場の促進要因
• デジタルセラピューティクス市場の抑制要因と課題
• デジタルセラピューティクス市場の機会

第5章 デジタルセラピューティクス市場のポーターのファイブフォース分析

第6章 デジタルセラピューティクス市場のレイアウト

• 用途別
  • 予防
  • 管理
  • 治療
• 適応症別
  • 糖尿病
  • 肥満
  • 心血管疾患
  • 呼吸器疾患
  • その他
• 地域
  • 北米のデジタルセラピューティクスの市場規模（2021年～2030年）
  • 欧州のデジタルセラピューティクスの市場規模（2021年～2030年）
  • アジア太平洋のデジタルセラピューティクスの市場規模（2021年～2030年）
  • その他の地域のデジタルセラピューティクスの市場規模（2021年～2030年）

第7章 デジタルセラピューティクス市場の企業と製品のプロファイル

• Limbix Health, Inc.
• GAIA AG
• BigHealth
• DarioHealth Corp
• HYGIEIA
• Akili, Inc
• Pear Therapeutics (US), Inc.
• CANARY HEALTH
• Noom, Inc.
• Omada Health Inc.
• Welldoc, Inc.
• 2Morrow, Inc
• ResMed
• Teladoc Health, Inc.
• Fitbit Health Solutions

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Digital Therapeutics Market in Global (2021-2030)
• Table 3: Digital Therapeutics Market in Global by Application (2021-2030)
• Table 4: Digital Therapeutics Market in Global by Indication (2021-2030)
• Table 5: Digital Therapeutics Market in Global by Geography (2021-2030)
• Table 6: Digital Therapeutics Market in North America (2021-2030)
• Table 7: Digital Therapeutics Market in the US (2021-2030)
• Table 8: Digital Therapeutics Market in Canada (2021-2030)
• Table 9: Digital Therapeutics Market in Mexico (2021-2030)
• Table 10: Digital Therapeutics Market in Europe (2021-2030)
• Table 11: Digital Therapeutics Market in France (2021-2030)
• Table 12: Digital Therapeutics Market in Germany (2021-2030)
• Table 13: Digital Therapeutics Market in the United Kingdom (2021-2030)
• Table 14: Digital Therapeutics Market in Italy (2021-2030)
• Table 15: Digital Therapeutics Market in Spain (2021-2030)
• Table 16: Digital Therapeutics Market in the Rest of Europe (2021-2030)
• Table 17: Digital Therapeutics Market in Asia-Pacific (2021-2030)
• Table 18: Digital Therapeutics Market in China (2021-2030)
• Table 19: Digital Therapeutics Market in Japan (2021-2030)
• Table 20: Digital Therapeutics Market in India (2021-2030)
• Table 21: Digital Therapeutics Market in Australia (2021-2030)
• Table 22: Digital Therapeutics Market in South Korea (2021-2030)
• Table 23: Digital Therapeutics Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Digital Therapeutics Market in the Rest of the World (2021-2030)
• Table 25: Digital Therapeutics Market in the Middle East (2021-2030)
• Table 26: Digital Therapeutics Market in Africa (2021-2030)
• Table 27: Digital Therapeutics Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Digital Therapeutics Market in Global (2021-2030)
• Figure 3: Digital Therapeutics Market in Global by Application (2021-2030)
• Figure 4: Digital Therapeutics Market in Global by Indication (2021-2030)
• Figure 5: Digital Therapeutics Market in Global by Geography (2021-2030)
• Figure 6: Digital Therapeutics Market in North America (2021-2030)
• Figure 7: Digital Therapeutics Market in the US (2021-2030)
• Figure 8: Digital Therapeutics Market in Canada (2021-2030)
• Figure 9: Digital Therapeutics Market in Mexico (2021-2030)
• Figure 10: Digital Therapeutics Market in Europe (2021-2030)
• Figure 11: Digital Therapeutics Market in France (2021-2030)
• Figure 12: Digital Therapeutics Market in Germany (2021-2030)
• Figure 13: Digital Therapeutics Market in the United Kingdom (2021-2030)
• Figure 14: Digital Therapeutics Market in Italy (2021-2030)
• Figure 15: Digital Therapeutics Market in Spain (2021-2030)
• Figure 16: Digital Therapeutics Market in the Rest of Europe (2021-2030)
• Figure 17: Digital Therapeutics Market in Asia-Pacific (2021-2030)
• Figure 18: Digital Therapeutics Market in China (2021-2030)
• Figure 19: Digital Therapeutics Market in Japan (2021-2030)
• Figure 20: Digital Therapeutics Market in India (2021-2030)
• Figure 21: Digital Therapeutics Market in Australia (2021-2030)
• Figure 22: Digital Therapeutics Market in South Korea (2021-2030)
• Figure 23: Digital Therapeutics Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Digital Therapeutics Market in the Rest of the World (2021-2030)
• Figure 25: Digital Therapeutics Market in the Middle East (2021-2030)
• Figure 26: Digital Therapeutics Market in Africa (2021-2030)
• Figure 27: Digital Therapeutics Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Digital Therapeutics Market By Application (Prevention, Management, And Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing accessibility of virtual care and shifting focus among the population on lowering the healthcare cost

The global digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030. The demand for digital therapeutics is being boosted by the increasing prevalence of chronic diseases such as diabetes, mental illness, cancer, and heart failure (HF), advancements in technology such as the continuous advancements in mobile technology, wearable devices, artificial intelligence, machine learning, and data analytics have facilitated the development of more sophisticated and effective digital therapeutics solutions. Rising healthcare cost as healthcare costs have been steadily increasing in many countries. Digital therapeutics offer an opportunity to reduce healthcare expenses by providing remote and efficient healthcare delivery, reducing the need for frequent hospital visits, and preventing costly complications associated with chronic diseases. Regulatory support, growing acceptance among healthcare professionals, health insurance coverage, and strategic partnerships and investments among others are some of the major factors contributing to the overall growth of the digital therapeutics market and driving the market growth during the forecast period from 2024-2030.

Digital Therapeutics Market Dynamics:

As per the International Diabetes Federation 2022, in the year 2021, approximately 537 million people were living with diabetes, globally. As per the aforementioned source, the total number of patients suffering from diabetes is projected to grow to about 643 million patients by the year 2030 and about 783 million people by 2045.

Digital therapeutic applications (DTx) such as Blue Star, Diabeo System, Livongo Diabetes Program, and Tidepool, among others, use web-based applications or cloud platforms to provide an evidence-based, personalized, rapid point-of-care management of chronic, behavior-modifiable conditions, including diabetes mellitus. DTx can improve patient compliance, therapeutic success, and economic outcomes in diabetes management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Thus, the rising prevalence of diabetes will increase the demand for digital therapeutic software which are used in the management and treatment of diabetes, thereby propelling the overall market of digital therapeutics.

The market is anticipated to be driven by rising smartphone adoption in both developed and developing nations, the affordability of digital health technology for patients and providers, and rising demand for patient-centered care and integrated healthcare systems. Kepios estimates that 4.27 billion people used the internet worldwide in April 2021, making up more than 60% of the world's population. It is anticipated that as this number rises, so will public awareness of smart health tracking. Additionally, it is projected that the COVID-19 pandemic, helpful regulatory actions, early indications of reimbursement, and the rising prevalence of chronic diseases will fuel market expansion.

The increasing focus of major key players on developing such technologically advanced software with easy access for physicians and patients is expected to propel the market during the forecast period. For instance, in July 2022, AmerisourceBergen Corporation launched DTx Connect, a fully integrated ordering, dispensing, and fulfillment platform that aims to facilitate patient access to physician-ordered therapeutics and diagnostics. The platform integrates with electronic medical records (EMR), giving physicians easy access to prescription and non-prescription therapies.

Therefore, the above-mentioned factors are contributing to the growth of the digital therapeutics market during the forecast period from 2024-2030.

However, cybersecurity and privacy concerns, unstable payment models, and others may restrict the digital therapeutics market growth.

Digital Therapeutics Market Segment Analysis:

Digital Therapeutics Market by Application (Prevention, Management, and Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the digital therapeutics market, the obesity category is expected to amass a significant revenue share in the year 2023. This can be attributed to the increasing statistics of obesity across the globe.

The World Obesity Atlas 2022, published by the World Obesity Federation, predicts that one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. Obesity is a major public health challenge that affects almost every country in the world. Globally, obesity rates have been increasing steadily over the last three decades. In almost every region, there are now more people living with obesity than underweight, and if current numbers continue to rise, as many as 1 billion adults, or 12% of the world population, will be living with obesity by 2025. The above-mentioned source also stated that almost 2.3 billion children and adults were living with overweight and obesity, in 2022, globally and if current trends continue, 2.7 billion adults could be living with overweight or obesity by 2025.

World Health Organization (WHO) European Regional Obesity Report 2022, stated that overweight and obesity affect almost 60% of adults and nearly one in three children (29% of boys and 27% of girls) in the WHO European Region, in 2022.

The use of a digital therapeutics platform in people with obesity and metabolic syndrome can lead to a reduction in both weight and body mass index (BMI), thereby reducing the risk for comorbidities. Digital therapeutic platforms allow clinicians to deliver lifestyle-modification interventions remotely. These interventions have the potential to influence weight loss in people with obesity and metabolic syndrome through the delivery of evidence-based care even in settings that are resource-limited.

Thus, the increasing prevalence of obesity and overweight will increase the demand for digital therapeutics for managing and treating obesity and overweight.

The WDTx Platform by Wellthy Therapeutics Pvt Ltd. provides a 52-week lifestyle modification program focused on diet, physical activity, weight management, remote patient monitoring, glycemic control, and blood pressure control. The platform provides artificial intelligence-augmented healthcare tracking, evidence-backed content, and personalized health coach support.

Thus, the above-mentioned factors are likely to propel the demand for obesity-managing digital therapeutics, thereby contributing to the growth of the digital therapeutics market during the forecast period from 2024-2030.

North America is expected to dominate the overall Digital Therapeutics Market:

Among all the regions, North America is estimated to account for the largest share of the Digital Therapeutics market in the year 2023. This domination is due to the increasing demand for digital therapeutics among the physicians and patients in the region, the increasing patient pool suffering from chronic diseases, the rising demand for remote patient monitoring and telemedicine, the presence of key market players among the key factors that contribute to the growth of the digital therapeutics, among others will propel the market of digital therapeutics in North America.

The rising burden of the geriatric patient population in the region will increase the demand for digital therapeutics as elderly patients are more prone to chronic diseases. The U.S. Census Bureau, Population Projections, latest data reported that the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and the 65-and-older age group's share of the total population will rise from 16 percent to 23 percent.

The favorable regulatory authorities will propel the overall market of digital therapeutics in the region. For instance, in April 2020, the Food and Drug Administration of the US released guidelines and planned to expand the accessibility of digital therapeutic devices for psychiatric patients. It was aimed to subsidize those people who followed the guidelines and practiced social isolation without a clinic visit during the COVID-19 pandemic situation

Furthermore, the growing healthcare IT expenditure to advance infrastructure, technological literacy, readiness to adopt advanced technological solutions, favorable government initiatives, the emergence of startups, lucrative funding options growing smartphone penetration, and advancements in internet connectivity, will propel the demand for digital therapeutics in North America.

Some of the major players in this region are Proteus Digital Health, Inc., Omada Health, Inc., WellDoc, Inc., and Livongo Health, Inc.

Thus, all the above-mentioned factors will lead to an increase in the North America Digital Therapeutics market growth during the forecasting period of 2024-2030.

Digital Therapeutics Market Key Players:

Some of the key market players operating in the digital therapeutics market include Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, and others.

Recent Developmental Activities in the Digital Therapeutics Market:

In January 2023, Lupin Digital Health, a wholly-owned subsidiary of global pharma major Lupin Limited, launched its digital therapeutics solution, LYFE. LYFE is India's only evidence-based holistic heart care program that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients

In May 2022, International digital therapeutics innovator, Sidekick Health, launched an integrated digital therapeutics solution for improving the outcomes of patients with Atopic Dermatitis (AD) in conjunction with Pfizer Inc. Sidekick and Pfizer will roll out their integrated digital therapeutics offering, launching first in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later in 2022.

In June 2020, the FDA cleared the first video game for children with attention deficit hyperactivity disorder (ADHD), allowing Akili Interactive's EndeavorRx to be prescribed as a digital therapeutic.

In April 2021, Mahana Therapeutics, Inc. received the US FDA 510(K) marketing clearance for its Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) mobile application, it is substantially equivalent to a marketed predicate device for Irritable Bowel Syndrome (IBS)

Key Takeaways from the Digital Therapeutics Market Report Study

Market size analysis for current digital therapeutics market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global digital therapeutics market.

Various opportunities are available for the other competitors in the digital therapeutics market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current digital therapeutics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for digital therapeutics market growth in the coming future?

Target Audience who can be benefited from this Digital Therapeutics Market Report Study

Digital therapeutics products providers

Research organizations and consulting companies

Digital therapeutics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in digital therapeutics

Various End-users who want to know more about the digital therapeutics market and the latest technological developments in the digital therapeutics market.

Frequently Asked Questions for the Digital Therapeutics Market:

1. What are digital therapeutics?

Digital Therapeutics (DTx) are evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease. In other words, DTx is a patient-facing software application that helps patients treat, prevent, or manage the disease and that has a proven clinical benefit.

2. What is the market for global digital therapeutics?

The global digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the global digital therapeutics market?

The demand for digital therapeutics is primarily being heightened by the growing geriatric population prone to chronic diseases, the rising number of patients pool suffering from chronic diseases, the increasing usage of smartphones for digital therapeutics, the rising use of health monitoring apps, the cost-effectiveness of digital health technology for providers & patients, and increasing demand for integrated healthcare systems & patient-centric care among others, thereby contribute to the overall growth of the digital therapeutics market during the forecast period from 2024-2030.

4. Who are the key players operating in the global digital therapeutics market?

Some of the key market players operating in the digital therapeutics market include Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, and others.

5. Which region has the highest share in the digital therapeutics market?

North America is expected to dominate the overall digital therapeutics market during the forecast period from 2024-2030. Factors such as the growing prevalence of chronic disorders such as diabetes, cardiovascular diseases, and cancers, among others, and the increasing geriatric population prone to chronic diseases will positively impact the North American digital therapeutics market. Furthermore, high disposable income, sophisticated healthcare infrastructure, incremental healthcare expenditure, an increasing number of start-ups, a well-developed healthcare sector, and increasing investments for R&D, among others also helped the market growth in this region.

Table of Contents

1. Digital Therapeutics Market Report Introduction

2. Digital Therapeutics Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Digital Therapeutics Market Key Factors Analysis

• 4.1. Digital Therapeutics Market Drivers
  • 4.1.1. Growing demand for remote patient monitoring and mobile health applications
  • 4.1.2. Increasing prevalence of chronic diseases
  • 4.1.3. Advancements in digital healthcare, IoT, AI, and others
• 4.2. Digital Therapeutics Market Restraints and Challenges
  • 4.2.1. Cybersecurity and privacy concerns
  • 4.2.2. Unstable payment models
• 4.3. Digital Therapeutics Market Opportunities
  • 4.3.1. Increasing supportive initiatives and strategic alliances among the key players to grow the market of digital therapeutics

5. Digital Therapeutics Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Digital Therapeutics Market Layout

• 6.1. By Application
  • 6.1.1. Prevention
  • 6.1.2. Management
  • 6.1.3. Treatment
• 6.2. By Indication
  • 6.2.1. Diabetes
  • 6.2.2. Obesity
  • 6.2.3. Cardiovascular Diseases
  • 6.2.4. Respiratory Diseases
  • 6.2.5. Others
• 6.3. By Geography
  • 6.3.1. North America Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.1.1. United States Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.1.2. Canada Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.1.3. Mexico Digital Therapeutics Market Size in USD million (2021-2030)
  • 6.3.2. Europe Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2.1. France Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2.2. Germany Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2.3. United Kingdom Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2.4. Italy Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2.5. Spain Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2.6. Rest of Europe Digital Therapeutics Market Size in USD million (2021-2030)
  • 6.3.3. Asia-Pacific Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3.1. China Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3.2. Japan Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3.3. India Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3.4. Australia Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3.5. South Korea Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3.6. Rest of the Asia-Pacific Digital Therapeutics Market Size in USD million (2021-2030)
  • 6.3.4. Rest of the World (RoW) Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.4.1. Middle East Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.4.2. Africa Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.4.3. South America Digital Therapeutics Market Size in USD million (2021-2030)

7. Digital Therapeutics Market Company and Product Profiles

• 7.1. Limbix Health, Inc.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. GAIA AG
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. BigHealth
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. DarioHealth Corp
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. HYGIEIA
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Akili, Inc
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. Pear Therapeutics (US), Inc.
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. CANARY HEALTH
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. Noom, Inc.
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. Omada Health Inc.
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Welldoc, Inc.
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. 2Morrow, Inc
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. ResMed
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Teladoc Health, Inc.
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Fitbit Health Solutions
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us